Original Article: bit.ly/1u7BUn2
The number of people using Truvada for pre-exposure prophylaxis (PrEP) in the US is increasing and a growing proportion of users are men, according to an analysis of data from approximately half of American pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of antiretroviral medications to prevent HIV infection. Gilead Sciences’ Truvada (tenofovir + emtricitabine) taken once daily was shown to be effective in the iPrEx study of mostly gay and bisexual men, reducing the risk of HIV infection by 42% overall, rising to 92% among participants with blood drug levels indicating regular use. A mathematical model suggested that taking Truvada four times per week would provide 99% protection, and in an open-label extension of iPrEx none of the men who took Truvada at least this often became infected.
The US Food and Drug Administration (FDA) approved once-daily Truvada for PrEP in July 2012. In May of this year, the US Centers for Disease Control and Prevention (CDC) recommended that people at ‘substantial risk’ should consider PrEP to prevent HIV infection, and the World Health Organization (WHO) has also recommended PrEP as an option for at-risk gay men.
Yet uptake of Truvada PrEP has not been as widespread as many had hoped, facing barriers such as lack of awareness among people at risk for HIV, resistance from some medical providers and inconsistent insurance coverage.
Full text of article available at link below: bit.ly/1u7BUn2